(NASDAQ: ENGN) Engene Holdings's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.46%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.97%.
Engene Holdings's revenue in 2024 is N/A.On average, 1 Wall Street analysts forecast ENGN's revenue for 2026 to be $1,798,601,530, with the lowest ENGN revenue forecast at $1,798,601,530, and the highest ENGN revenue forecast at $1,798,601,530. On average, 1 Wall Street analysts forecast ENGN's revenue for 2027 to be $5,696,951,588, with the lowest ENGN revenue forecast at $5,696,951,588, and the highest ENGN revenue forecast at $5,696,951,588.
In 2028, ENGN is forecast to generate $10,708,804,653 in revenue, with the lowest revenue forecast at $10,708,804,653 and the highest revenue forecast at $10,708,804,653.